ROPIVACAINE HYDROCHLORIDE INJECTION USP SOLUTION

国: カナダ

言語: 英語

ソース: Health Canada

有効成分:

ROPIVACAINE HYDROCHLORIDE

から入手可能:

PFIZER CANADA ULC

ATCコード:

N01BB09

INN（国際名）:

ROPIVACAINE

投薬量:

10MG

医薬品形態:

SOLUTION

構図:

ROPIVACAINE HYDROCHLORIDE 10MG

投与経路:

EPIDURAL

パッケージ内のユニット:

10ML/20ML

処方タイプ:

Ethical

治療領域:

LOCAL ANESTHETICS

製品概要:

Active ingredient group (AIG) number: 0133273005; AHFS:

認証ステータス:

CANCELLED POST MARKET

承認日:

2022-10-01

製品の特徴

_Product Monograph – Ropivacaine Hydrochloride Injection USP _
_Page 1 of 38_
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
ROPIVACAINE HYDROCHLORIDE INJECTION USP
Parenteral sterile solution
2 mg / mL ropivacaine hydrochloride per flexible container
5 mg / mL and 10 mg / mL ropivacaine hydrochloride per vial
Local Anaesthetic
Pfizer Canada ULC
17300 Trans-Canada Highway
Kirkland, Québec
H9J 2M5
Date of Revision:
May 19, 2020
Submission Control No: 236564
_ _
_Product Monograph – Ropivacaine Hydrochloride Injection USP _
_Page 2 of 38_
RECENT MAJOR LABEL CHANGES
Warnings and Precautions (6)
10/2018
TABLE OF CONTENTS
RECENT MAJOR LABEL CHANGES
........................................................................................
2
TABLE OF CONTENTS
.............................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
................................................................. 4
1
INDICATIONS
.................................................................................................................
4
1.1
Pediatrics
...............................................................................................................
4
1.2
Geriatrics
...............................................................................................................
4
2
CONTRAINDICATIONS
..................................................................................................
4
3
DOSAGE AND ADMINISTRATION
................................................................................
5
3.1
Dosing Considerations
...........................................................................................
5
3.2
Recommended Dose and Dosage Adjustment
....................................................... 6
4
OVERDOSAGE
...............................................................................................................
7
5
DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING
......................... 9
6